Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Flynn

Showing results (891-900 of 1,011) with videos related to

Pageof 102
Sort By:
Journal of Neuro-Oncology|May 24, 2019
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.
Journal of Neuro-Oncology|June 6, 2019
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.
NPJ Breast Cancer|May 21, 2021
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumabPatricia A Ganz, Reena S Cecchini, Louis Fehrenbacher, et al.
Nature Medicine|June 15, 2007
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania majorPatricia A Darrah, Dipti T Patel, Paula M De Luca, et al.
The Journal of Community and Supportive Oncology|August 20, 2015
Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106Kathryn M Greven, L Douglas Case, Lawrence R Nycum, et al.
Urology|July 28, 2023
Clinical Validation of an Adult-acquired Buried Penis Classification System Based on Standardized Evaluation of the Penis, Abdomen, and ScrotumCharles H Schlaepfer, Kevin J Flynn, Nejd F Alsikafi, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2013
IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contractionJillian L Barlow, Samantha Peel, Jane Fox, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2010
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074Joon H Uhm, Karla V Ballman, Wenting Wu, et al.
Cell Reports|February 16, 2022
The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malariaLawrence T Wang, Nicholas K Hurlburt, Arne Schön, et al.
Breast Cancer Research and Treatment|January 1, 1981
Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trialC A Hubay, O H Pearson, J S Marshall, et al.
Pageof 102

Showing results (891-900 of 1,011) with videos related to

Sort By:
Pageof 102
Journal of Neuro-Oncology|May 24, 2019
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.
Journal of Neuro-Oncology|June 6, 2019
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.
NPJ Breast Cancer|May 21, 2021
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumabPatricia A Ganz, Reena S Cecchini, Louis Fehrenbacher, et al.
Nature Medicine|June 15, 2007
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania majorPatricia A Darrah, Dipti T Patel, Paula M De Luca, et al.
The Journal of Community and Supportive Oncology|August 20, 2015
Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106Kathryn M Greven, L Douglas Case, Lawrence R Nycum, et al.
Urology|July 28, 2023
Clinical Validation of an Adult-acquired Buried Penis Classification System Based on Standardized Evaluation of the Penis, Abdomen, and ScrotumCharles H Schlaepfer, Kevin J Flynn, Nejd F Alsikafi, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2013
IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contractionJillian L Barlow, Samantha Peel, Jane Fox, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2010
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074Joon H Uhm, Karla V Ballman, Wenting Wu, et al.
Cell Reports|February 16, 2022
The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malariaLawrence T Wang, Nicholas K Hurlburt, Arne Schön, et al.
Breast Cancer Research and Treatment|January 1, 1981
Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trialC A Hubay, O H Pearson, J S Marshall, et al.
Pageof 102